Marker Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.17%) and Concourse Financial Group Securities Inc. (0.00%).
Is marker Therapeutics a good stock to buy?
Only 21.20% of the stock of Marker Therapeutics is held by institutions. Marker Therapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Does marker Therapeutics's stock have much upside?
Does Marker Therapeutics's stock price have much upside? According to analysts, Marker Therapeutics's stock has a predicted upside of 397.68% based on their 12-month price targets. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
